Emendo
Business Services · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
727 W Hargett St Ste 101, Raleigh, North...Phone Number
+45 21193410Website
www.emendo.comRevenue
$24.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Emendo
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo's novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas.Explore more
Emendo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Emendo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Emendo is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Emendo recently announced quarterly report
Funding: Get notified immidiatlly once Emendo has new funding data
Emendo, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Emendo
Click to see if Emendo had a recent Job posting/layoffs
Product Launch: Get notified when Emendo launches new products
Check if Emendo has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Emendo as Masked Content
Find 3 more new buyers
Compare Similar Companies to Emendo
Compare insights from companies similar to Emendo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Emendo is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Emendo is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Emendo.
Emendo Tech Stack
A closer look at the technologies used by Emendo
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Emendo
Sign Up For FreeTo access detailed company insights
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo's novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform ena... Read More
